|

Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention

RECRUITINGPhase 4Sponsored by National Institute of Cardiovascular Diseases, Pakistan
Actively Recruiting
PhasePhase 4
SponsorNational Institute of Cardiovascular Diseases, Pakistan
Started2025-06-01
Est. completion2026-05-30
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07536802

Summary

Primary objective of the study is to evaluate the impact of adenosine pre-medication on incidence of slow flow/no-reflow after primary percutaneous coronary intervention.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* All patients with acute STEMI undergoing primary PCI
* Patients of either sex, ≥18 years of age.

Exclusion Criteria:

* STEMI patients with cardiogenic shock at presentation
* Patients with heart block
* Allergy to adenosine
* Patients refuse to give consent for participation

Conditions5

Acute Myocardial InfarctionCoronary Slow FlowHeart DiseaseNo-Reflow PhenomenonST-segment Elevation Myocardial Infarction (STEMI)

Interventions1

Adenosine pre-medication

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.